Anti-Cd20/Cd30-Car-T Cells
Relapsed/Refractory Leukemia
Affiliated Hospital of Nantong UniversityCell therapyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Relapsed/Refractory Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Anti-Cd19 Car T-Cells Affiliated Hospital of Nantong University | Early Phase 1 | C |
Same molecule, other indications
Anti-Cd20/Cd30-Car-T Cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →